vs
Orion S.A.（OEC）与Orthofix Medical Inc.（OFIX）财务数据对比。点击上方公司名可切换其他公司
Orion S.A.的季度营收约是Orthofix Medical Inc.的1.9倍（$411.7M vs $219.9M），Orthofix Medical Inc.同比增速更快（2.0% vs -5.2%），Orion S.A.自由现金流更多（$44.2M vs $16.8M），过去两年Orthofix Medical Inc.的营收复合增速更高（8.0% vs -9.5%）
奥里昂集团成立于1917年，总部位于芬兰埃斯波，是一家全球化运营的芬兰企业。公司面向全球市场研发、生产并销售人用与兽用药品以及药用活性成分，旗下所有生产基地及大部分研发部门均设于芬兰境内。
Orthofix医疗是全球知名骨科医疗器械企业，专注于研发、生产及销售脊柱植入物、骨科创伤产品、骨生长刺激治疗设备及再生医疗产品，服务全球多地的骨科医师与医疗机构，致力于提升肌肉骨骼疾病患者的诊疗效果。
OEC vs OFIX — 直观对比
营收规模更大
OEC
是对方的1.9倍
$219.9M
营收增速更快
OFIX
高出7.2%
-5.2%
自由现金流更多
OEC
多$27.4M
$16.8M
两年增速更快
OFIX
近两年复合增速
-9.5%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $411.7M | $219.9M |
| 净利润 | — | $-2.2M |
| 毛利率 | 18.9% | 71.1% |
| 营业利润率 | 4.3% | 0.2% |
| 净利率 | — | -1.0% |
| 营收同比 | -5.2% | 2.0% |
| 净利润同比 | — | 92.4% |
| 每股收益（稀释后） | $-0.36 | $-0.05 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收OECOFIX
| Q4 25 | $411.7M | $219.9M | ||
| Q3 25 | $450.9M | $205.6M | ||
| Q2 25 | $466.4M | $203.1M | ||
| Q1 25 | $477.7M | $193.6M | ||
| Q4 24 | $434.2M | $215.7M | ||
| Q3 24 | $463.4M | $196.6M | ||
| Q2 24 | $477.0M | $198.6M | ||
| Q1 24 | $502.9M | $188.6M |
净利润OECOFIX
| Q4 25 | — | $-2.2M | ||
| Q3 25 | $-67.1M | $-22.8M | ||
| Q2 25 | $9.0M | $-14.1M | ||
| Q1 25 | $9.1M | $-53.1M | ||
| Q4 24 | — | $-29.1M | ||
| Q3 24 | $-20.2M | $-27.4M | ||
| Q2 24 | $20.5M | $-33.4M | ||
| Q1 24 | $26.7M | $-36.0M |
毛利率OECOFIX
| Q4 25 | 18.9% | 71.1% | ||
| Q3 25 | 19.0% | 72.2% | ||
| Q2 25 | 21.1% | 68.7% | ||
| Q1 25 | 20.5% | 62.8% | ||
| Q4 24 | 20.6% | 69.0% | ||
| Q3 24 | 23.2% | 68.7% | ||
| Q2 24 | 23.0% | 67.8% | ||
| Q1 24 | 24.3% | 67.5% |
营业利润率OECOFIX
| Q4 25 | 4.3% | 0.2% | ||
| Q3 25 | -11.9% | -8.3% | ||
| Q2 25 | 6.9% | -7.9% | ||
| Q1 25 | 6.5% | -25.2% | ||
| Q4 24 | 5.4% | -5.3% | ||
| Q3 24 | -3.3% | -9.6% | ||
| Q2 24 | 8.7% | -12.5% | ||
| Q1 24 | 10.5% | -15.6% |
净利率OECOFIX
| Q4 25 | — | -1.0% | ||
| Q3 25 | -14.9% | -11.1% | ||
| Q2 25 | 1.9% | -6.9% | ||
| Q1 25 | 1.9% | -27.4% | ||
| Q4 24 | — | -13.5% | ||
| Q3 24 | -4.4% | -13.9% | ||
| Q2 24 | 4.3% | -16.8% | ||
| Q1 24 | 5.3% | -19.1% |
每股收益（稀释后）OECOFIX
| Q4 25 | $-0.36 | $-0.05 | ||
| Q3 25 | $-1.20 | $-0.57 | ||
| Q2 25 | $0.16 | $-0.36 | ||
| Q1 25 | $0.16 | $-1.35 | ||
| Q4 24 | $0.31 | $-0.76 | ||
| Q3 24 | $-0.35 | $-0.71 | ||
| Q2 24 | $0.35 | $-0.88 | ||
| Q1 24 | $0.45 | $-0.95 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $60.7M | $82.0M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $384.6M | $450.0M |
| 总资产 | $1.9B | $850.6M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资OECOFIX
| Q4 25 | $60.7M | $82.0M | ||
| Q3 25 | $51.3M | $62.9M | ||
| Q2 25 | $42.6M | $65.6M | ||
| Q1 25 | $37.5M | $58.0M | ||
| Q4 24 | $44.2M | $83.2M | ||
| Q3 24 | $53.2M | $30.1M | ||
| Q2 24 | $34.2M | $26.4M | ||
| Q1 24 | $43.9M | $27.0M |
总债务OECOFIX
| Q4 25 | — | — | ||
| Q3 25 | — | $157.2M | ||
| Q2 25 | — | $157.0M | ||
| Q1 25 | — | $156.9M | ||
| Q4 24 | — | $157.0M | ||
| Q3 24 | — | $118.5M | ||
| Q2 24 | — | $118.0M | ||
| Q1 24 | — | $118.2M |
股东权益OECOFIX
| Q4 25 | $384.6M | $450.0M | ||
| Q3 25 | $401.8M | $442.5M | ||
| Q2 25 | $466.5M | $458.3M | ||
| Q1 25 | $466.1M | $458.3M | ||
| Q4 24 | $474.9M | $503.1M | ||
| Q3 24 | $476.3M | $525.9M | ||
| Q2 24 | $503.9M | $546.0M | ||
| Q1 24 | $492.2M | $570.3M |
总资产OECOFIX
| Q4 25 | $1.9B | $850.6M | ||
| Q3 25 | $2.0B | $832.6M | ||
| Q2 25 | $2.0B | $837.2M | ||
| Q1 25 | $2.0B | $823.1M | ||
| Q4 24 | $1.9B | $893.3M | ||
| Q3 24 | $2.0B | $867.9M | ||
| Q2 24 | $1.9B | $882.0M | ||
| Q1 24 | $1.9B | $906.0M |
负债/权益比OECOFIX
| Q4 25 | — | — | ||
| Q3 25 | — | 0.36× | ||
| Q2 25 | — | 0.34× | ||
| Q1 25 | — | 0.34× | ||
| Q4 24 | — | 0.31× | ||
| Q3 24 | — | 0.23× | ||
| Q2 24 | — | 0.22× | ||
| Q1 24 | — | 0.21× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $92.9M | $27.7M |
| 自由现金流经营现金流 - 资本支出 | $44.2M | $16.8M |
| 自由现金流率自由现金流/营收 | 10.7% | 7.6% |
| 资本支出强度资本支出/营收 | 11.8% | 4.9% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $54.8M | $-1.3M |
8季度趋势，按日历期对齐
经营现金流OECOFIX
| Q4 25 | $92.9M | $27.7M | ||
| Q3 25 | $68.8M | $12.4M | ||
| Q2 25 | $53.7M | $11.6M | ||
| Q1 25 | $400.0K | $-18.4M | ||
| Q4 24 | $94.5M | $23.7M | ||
| Q3 24 | $-30.9M | $11.7M | ||
| Q2 24 | $29.3M | $9.0M | ||
| Q1 24 | $32.4M | $-18.6M |
自由现金流OECOFIX
| Q4 25 | $44.2M | $16.8M | ||
| Q3 25 | $27.9M | $2.5M | ||
| Q2 25 | $11.5M | $4.5M | ||
| Q1 25 | $-28.8M | $-25.1M | ||
| Q4 24 | $23.5M | $15.2M | ||
| Q3 24 | $-78.8M | $6.3M | ||
| Q2 24 | $-25.4M | $-360.0K | ||
| Q1 24 | $-700.0K | $-29.1M |
自由现金流率OECOFIX
| Q4 25 | 10.7% | 7.6% | ||
| Q3 25 | 6.2% | 1.2% | ||
| Q2 25 | 2.5% | 2.2% | ||
| Q1 25 | -6.0% | -13.0% | ||
| Q4 24 | 5.4% | 7.0% | ||
| Q3 24 | -17.0% | 3.2% | ||
| Q2 24 | -5.3% | -0.2% | ||
| Q1 24 | -0.1% | -15.4% |
资本支出强度OECOFIX
| Q4 25 | 11.8% | 4.9% | ||
| Q3 25 | 9.1% | 4.8% | ||
| Q2 25 | 9.0% | 3.5% | ||
| Q1 25 | 6.1% | 3.5% | ||
| Q4 24 | 16.4% | 4.0% | ||
| Q3 24 | 10.3% | 2.7% | ||
| Q2 24 | 11.5% | 4.7% | ||
| Q1 24 | 6.6% | 5.6% |
现金转化率OECOFIX
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 5.97× | — | ||
| Q1 25 | 0.04× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 1.43× | — | ||
| Q1 24 | 1.21× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
OEC
| Rubber | $272.0M | 66% |
| Specialties | $139.7M | 34% |
OFIX
| Spinal Implants Biologics And Enabling Technologies | $113.6M | 52% |
| Bone Growth Therapies | $68.3M | 31% |
| Other | $22.7M | 10% |
| IT | $5.9M | 3% |
| GB | $3.5M | 2% |
| FR | $3.5M | 2% |
| DE | $2.3M | 1% |
